Description: Nascent Biotech Inc. is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The Company is engaged in the research and development of the antibodies for control of brain and pancreatic cancer in humans. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company owns the license rights to a drug candidate, pritumumab, which it is developing. The Company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. Pritumumab is a monoclonal antibody. The Company has not generated revenues.
Home Page: www.nascentbiotech.com
623 17th Street
Vero Beach,
FL
32960
United States
Phone:
612 961 5656
Officers
| Name | Title |
|---|---|
| Mr. Sean Carrick | Pres, CEO, Sec. & Director |
| Mr. Lowell Holden | CFO, Chief Accounting Officer & Director |
| Dr. Mark C. Glassy | Founder & Chairman of Scientific Advisory Board |
| Dr. Navpaul Singh M.D. | Chief Medical Consultant |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.9097 |
| Price-to-Sales TTM: | 21.7794 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |